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Semen serves as a vehicle for HIV and promotes
sexual transmission of the virus, which accounts for
the majority of new HIV cases. The major component
of semen is the coagulum, a viscous structure com-
posed predominantly of spermatozoa and semeno-
gelin proteins. Due to the activity of the semen
protease PSA, the coagulum is liquefied and seme-
nogelins are cleaved into smaller fragments. Here,
we report that a subset of these semenogelin frag-
ments form amyloid fibrils that greatly enhance HIV
infection. Like SEVI, another amyloid fibril previously
identified in semen, the semenogelin fibrils exhibit
a cationic surface and enhance HIV virion attachment
and entry. Whereas semen samples from healthy
individuals greatly enhance HIV infection, semeno-
gelin-deficient semen samples from patients with
ejaculatory duct obstruction are completely deficient
in enhancing activity. Semen thus harbors distinct
amyloidogenic peptides derived from different pre-
cursor proteins that commonly enhance HIV infec-
tion and likely contribute to HIV transmission.
INTRODUCTION
Sexual transmission accounts for the vast majority of new HIV
infections, and semen is the vehicle fueling the global spread
of this retrovirus. We and others have demonstrated that semen
enhances in vitro HIV infection of multiple cell types, including
primary macrophages and CD4+ T cells, two biologically rele-
vant targets of HIV in vivo (Kim et al., 2010; Mu¨nch et al., 2007;
Olsen et al., 2010; Roan et al., 2009). Fractionation of a peptide
library generated from semen led to the identification of peptides
derived from prostatic acid phosphatase (PAP) that self-assem-Cell Host &bled into amyloid fibrils that greatly enhanced HIV infection
under conditions of limiting viral innocula (Mu¨nch et al., 2007).
The amyloids were termed semen-derived enhancers of viral
infection (SEVI).
We previously showed that SEVI enhances HIV infection by
promoting viral attachment to target cells (Mu¨nch et al., 2007;
Roan et al., 2009). SEVI is highly cationic (8 of its 39 residues
are positively charged at neutral pH), and the positive charges
of SEVI interact directly with the negatively charged surfaces of
target cells and HIV virions to promote attachment and fusion.
When the cationic property of SEVI is abrogated by site-directed
mutagenesis or by adding anionic polymers, SEVI loses its ability
to augment HIV infection (Roan et al., 2009). Importantly, anionic
polymers that inhibit the infection-enhancing activity of chemi-
cally synthesized SEVI also inhibit the enhancing activity of
semen (Roan et al., 2009), suggesting that endogenous SEVI
or other positively charged factors in semen play a role in its
ability to enhance viral infection.
We sought to confirm the role of positively charged factors
for the ability of semen to enhance HIV infection by depleting
these factors. In line with our previous data using anionic poly-
mers (Roan et al., 2009), semen depleted of positively charged
factors lost the ability to enhance HIV infection. Surprisingly,
when we identified the cationic factors that were specifically
depleted, we detected not SEVI but, rather, fragments from the
semenogelins (SEMs), which are abundant proteins in semen
that together with fibronectin constitute the semen coagulum,
a gelatinous structure crucial for fertilization (de Lamirande,
2007; Robert andGagnon, 1999). We further pursued this finding
and describe here the identification of peptides from SEMs that
form amyloids that enhance HIV infection. We further demon-
strate that variations in SEM levels directly correlate with
enhancement of HIV infection and that semen samples naturally
lacking SEMs are completely deficient in this effect. Altogether,
our data suggest that SEMs may play a previously unrecognized
role in promoting HIV infection in semen, thus indicating that
factors whose physiological purpose is to promote fertilization
may unfortunately also promote HIV transmission.Microbe 10, 541–550, December 15, 2011 ª2011 Elsevier Inc. 541
Figure 1. Seminal Fluid Depleted of
Cationic Factors Lacks Viral Enhancement
Activity
(A) Seminal fluid that was mock-treated, depleted
of cationic factors (SCX-depleted), or depleted of
anionic factors (SAX-depleted) was tested for the
ability to enhance HIV infection. 81A virions were
pretreated for 5 min with the indicated concen-
trations of seminal fluid and then diluted 15-fold
and added to TZM-bl cells. Medium was replaced
after 2 hr and cells were assayed for Tat-inducible
b-galactosidase activity 3 days later. The numbers
above the bars indicate the n-fold infectivity
enhancement relative to infection measured in the
absence of seminal fluid. RLU/s: relative light
units/second. Shown are average values (± stan-
dard deviations) of triplicate measurements from
one of three independent experiments that yielded
similar results. See also Figure S1.
(B) The total protein content of mock-treated,
SCX-depleted, or SAX-depleted seminal fluid was
assessed by the BCA assay. Shown are average
values (± standard deviations) of triplicate well
measurements from one of two independent
experiments that yielded similar results.
(C)Mock-treated, SCX-depleted, or SAX-depleted
seminal fluid was tested for relative reactivity to
WO1, an amyloid-specific antibody, by ELISA. The
reactivity of WO1 to PBS was subtracted from all
values. The OD (450–650 nm) indicates the relative
levels of WO1-reactive amyloids in each sample. *p < 0.005 versus mock-treated or SAX-depleted seminal fluid (two-tailed t test). Shown are average values (±
standard deviations) of triplicate well measurements from one of two independent experiments that yielded similar results.
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Seminal Fluid Depleted of Cationic Factors Is Deficient
in Enhancing HIV Infection
We previously demonstrated that the anionic polymers heparin
and dextran sulfate, but not less negatively charged polymers
suchaschondroitin sulfate, inhibit the ability of semen to enhance
HIV infection. Oversulfation of chondroitin sulfate converted this
polymer into a potent inhibitor, suggesting that anionic polymers
with higher concentrations of negative charges are more effec-
tive in inhibiting semen’s ability to enhance HIV infection (Roan
et al., 2009). These results suggest that positively charged factors
are responsible for the viral infection enhancing activity of semen.
To further test this hypothesis, we depleted cationic (i.e.,
positively charged) factors from seminal fluid (pooled from 20
donors) using strong cation exchange (SCX) beads. As negative
controls, we mock-depleted seminal fluid or depleted anionic
(i.e., negatively charged) factors with strong anion exchange
(SAX) beads. Depletion of positively charged factors, but not
negatively charged factors, abrogated the ability of semen to
enhance HIV infection of TZM-bl reporter cells (Figure 1A). Total
protein content was similar in the SCX- and SAX-depleted
seminal fluid (Figure 1B), suggesting that the absence of viral-
enhancing activity in SCX-depleted seminal fluid was not due
to the absence of protein.
Lack of Semenogelin Fragments in Seminal Fluid
Depleted of Cationic Factors
To identify the factors that were enriched in the SAX-depleted
seminal fluid (which enhanced HIV infection) relative to the542 Cell Host & Microbe 10, 541–550, December 15, 2011 ª2011 ElsSCX-depleted seminal fluid (which did not enhance HIV infec-
tion), we employed mass spectrometry. In two independent ex-
periments, matrix-assisted laser desorption ionization /tandem
mass spectrometry (MALDI MS/MS) detected exclusively
fragments from SEM1 and SEM2 (Table S1A), highly homolo-
gous proteins in semen that interact with fibronectin to form
the semen coagulum. This coagulum is progressively cleaved
by the protease prostate specific antigen (PSA) at specific sites
within the SEMs during semen liquefaction (Robert et al., 1997).
The SEM peptides identified by MALDI MS-MS included PSA-
generated proteolytic products (Robert et al., 1997) (Table
S1A). Although PAP248–286 or related fragments known to
form SEVI were not detected by MALDI MS/MS, when assessed
by ELISA, PAP248–286 was partially depleted by the SCX
beads (Figure S1). The depletion of SEM1 and SEM2 fragments
by SCX is not surprising, as both of these basic proteins are
positively charged at neutral pH. Because the SEMs were
deficient in seminal fluid depleted of viral-enhancing activity,
we pursued the possibility that SEMs, like SEVI, might corre-
spond to natural enhancers of HIV infection.
Semenogelin Fragments Form Amyloid Fibrils
We first investigated whether the SEMs were capable of
forming amyloid fibrils, with the rationale that if SEMs enhance
HIV infection like SEVI, they may also do so as an amyloid fibril.
Although to our knowledge no peptides from SEM have been
directly demonstrated to form amyloid fibrils, antibodies raised
against an N-terminal region of SEM1 (SEM1[45–64]) recognize
fibrillar structures isolated from the seminal vesicles of patients
with senile seminal vesicle amyloid (SSVA), one of the mostevier Inc.
Figure 2. Peptides from SEM1 and SEM2 Form Amyloid Fibrils
(A) The indicated that agitated peptides were mixed with 5 mM thioflavin T, and
the emissions at 482 nm were recorded. PAP248–286 is an amyloidogenic
peptide that polymerizes into SEVI (Mu¨nch et al., 2007). *p < 0.0005 versus
PBS control (two-tailed t test). Shown are average values (± standard
deviations) of triplicate well measurements from one of seven independent
experiments that yielded similar results. See Table S1 for peptide sequences.
(B) Electron micrographs of the fibrillar SEM peptides. Scale bars indicate
500 nm. Shown are results from one of two independent experiments that
yielded similar results.
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Because full-length SEMs are rare in semen due to the efficiency
of PSA cleavage (Koistinen et al., 2002; Robert et al., 1997), an
amyloid form of the SEMs in semen would likely be composed
of SEM fragments. To determine if we could identify amyloido-
genic fragments from semen, we took advantage of WO1, an
amyloid-specific antibody that recognizes the general amyloid
fold in a sequence-independent manner (O’Nuallain and Wetzel,
2002). WO1 had less reactivity to SCX-depleted seminal fluid
compared to mock-treated or SAX-depleted seminal fluid (Fig-
ure 1C), suggesting a relative deficiency of amyloids in seminal
fluid depleted of cationic factors. Another amyloid-specific anti-
body, OC (Kayed et al., 2007), also showed higher reactivity
to SAX-depleted seminal fluid compared to SCX-depleted
seminal fluid (data not shown). To identify the amyloid species,
we conjugated WO1 to magnetic beads and incubated themCell Host &with seminal fluid. Bead-bound material was digested with
trypsin and then identified by liquid chromatography (LC)
MALDI MS/MS. In three independent experiments, we identified
fragments from the N-terminus of the SEM proteins in WO1
samples and not from control samples, suggesting that SEM
amyloids might be present in semen. Interestingly, the identified
peptides were immediately C-terminal to SEM1(45–64), the
region that was suggested as amyloidogenic in SSVA patients
(Linke et al., 2005). We chemically synthesized a peptide corre-
sponding to SEM1(45–64) but found no evidence that it formed
amyloid fibrils when tested under multiple conditions (data not
shown). Because we had detected tryptic peptides immediately
downstream of SEM1(45–64), we reasoned that the region
C-terminal of SEM1(45–64) might be important for amyloid fibril
formation. Therefore, we chemically synthesized three peptides
harboring sequences C-terminal of SEM1(45–64): SEM1(45–
107), SEM1(49–107), and SEM1(68–107). The junctions following
residues 49 and 68 were chosen because they correspond to
natural PSA cleavage sites within SEM1 (Robert et al., 1997).
As such, peptides cleaved at these sites are likely to be present
in liquefied semen. The corresponding highly homologous
SEM2 peptides were also synthesized (Table S1B).
After overnight agitation at 37C to promote fibril formation,
SEM1(45–107), SEM2(45–107), SEM1(49–107), SEM2(49–107),
SEM1(68–107), and SEM2(68–107) all formed amyloid fibrils,
whereas SEM1(45–64) and a further downstream peptide,
SEM1(108–159), did not. Evidence for fibril formation included
an increase in the fluorescence intensity of thioflavin T (Fig-
ure 2A), binding of Congo red dye (data not shown), and detec-
tion of typical thread-like fibrillar structures by electron micros-
copy analyses (Figure 2B). Electron micrographs of the SEM
fibrils, together with HIV virions, demonstrated extensive inter-
actions between the two components (Figure 3A); these results
were further verified by fluorescence microscopy (Figure 3B).
Three-color imaging of the fibrils, virions, and cells suggested
that the fibrils promoted attachment of the virions to target
cells (Figure S2). Thus, peptides harboring sequences immedi-
ately C-terminal of SEM1(45–64), as well as SEM2 peptide
homologs, are capable of forming amyloid fibrils and interacting
with virions and cells.
Semenogelin Fibrils Enhance HIV Infection
We next tested whether these amyloid fibrils enhance HIV infec-
tion. Like SEVI, the SEM fibrils are rich in basic residues and,
thus, exhibit a net positive charge at neutral pH; isoelectric
points of the SEM peptides used in this study range from 8.16
to 10.12, as indicated in Table S1B. Because SEVI enhances
HIV fusion by promoting attachment of HIV virions to target
cells (Mu¨nch et al., 2007; Roan et al., 2009), we tested whether
SEM fibrils act in a similar manner. The six SEM peptides that
form fibrils enhanced fusion of CCR5-tropic HIV-1 81A virions
to primary CD4+ T cells (Figure 4A). In contrast, SEM1(45–64)
and SEM1(108–159), which fail to form fibrils (Figure 2A), did
not enhance viral fusion. Similar to SEVI, the enhancing effect
of the SEM fibrils was not coreceptor-specific, as fusion of
CXCR4-tropic HIV-1 NL4-3 to CD4+ T cells was similarly
enhanced (Figure 4B). Interestingly, the fibrils that were com-
posed of shorter peptides, SEM1(68–107) and SEM2(68–107),
enhanced fusion to a lesser extent than the fibrils formed withMicrobe 10, 541–550, December 15, 2011 ª2011 Elsevier Inc. 543
Figure 3. Visualization of Viral Particles Bound to SEM Fibrils
(A) Electron micrographs of SEM1(49–107) fibrils, HIV viral particles, and
SEM1(49–107) fibrils incubated together with the viral particles. Arrowheads
indicate examples of the sites of contact of virions with fibrils. Nonfibrillar
SEM1(45–64) and SEM1(108–159) were used as negative controls. Shown are
results from one of two independent experiments that yielded similar results.
(B) Fluorescence microscopy of SEM1(49–107) fibrils (red) and MLV-gag-YFP
viral particles (green). Shown are results from one of two independent exper-
iments that yielded similar results. See also Figure S2.
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107), and SEM2(49–107).
Similar to SEVI (Roan et al., 2009), the enhancing effect of
the SEM fibrils was dependent on their cationic property; using
the anionic polymer heparin to shield the fibrils’ positive charges
abrogated their viral-enhancing activities (Figure S3). Further-
more, when surface-exposed positive charges of the fibrils
were measured by zeta potential, we found that the SEM1(45–
107), SEM2(45–107), SEM1(49–107), and SEM2(49–107) fibrils
exhibited high potentials, whereas the two fibrils made up of
the shorter peptides, SEM1(68–107) and SEM2(68–107),544 Cell Host & Microbe 10, 541–550, December 15, 2011 ª2011 Elsexhibited low potentials (Table S1B). This decreased zeta poten-
tial may explain why the SEM1(68–107) and SEM2(68–107) fibrils
enhanced HIV fusion less potently than the other four. In support
of this possibility, the zeta potentials of the fibrils correlated
directly with the relative ability to enhance HIV fusion to target
cells (Figure S5A).
To determine if the SEM fibrils enhance productive infection,
we infected TZM-bl cells with an R5-tropic HIV-1 (Papkalla
et al., 2002) in the presence of increasing concentrations of the
fibrils. Each of the six SEM fibrils enhanced HIV infection (Fig-
ure 5). Although the relative levels of viral enhancement between
the different SEM fibrils varied between experiments, in general,
we observed that the fibrils derived from the shorter peptides,
SEM1(68–107) and SEM2(68–107), were less effective at
enhancing HIV infection. Finally, we demonstrated that SEM-
derived fibrils were capable of rescuing the viral-enhancing
activity of SCX-depleted seminal fluid (Figure S4).
Levels of Semenogelin Correlate with HIV-Enhancing
Activity in Semen Samples from Different Donors
To develop tools to assess endogenous levels of SEM frag-
ments, we generated polyclonal antibodies against fibrils
formed by the two fragments, SEM1(49–107) and SEM2(49–
107). Anti-SEM1(49–107) (hereafter called anti-S1) recognized
SEM1(49–107) in a dose-dependent manner and anti-SEM2
(49–107) (hereafter called anti-S2) recognized SEM2(49–107)
in a dose-dependent manner (Figure S5B). The antibodies
were not fibril-specific because they recognized the mono-
meric and fibrillar forms of the peptides to similar extents
(data not shown). When we compared the reactivities of anti-
S1 and anti-S2 to a standard curve, we found that the levels
of reactivity against the antisera in semen samples from 20
individuals corresponded to concentrations of antigen of 90–
3,000 mg/ml, well above the range necessary for enhancing
HIV infection.
We tested the relative ability of semen samples from 20 indi-
viduals to enhance HIV-1 infection of TZM-bl cells and plotted
this as a function of the relative levels of SEM1- and SEM2-
containing fragments as assessed using anti-S1 and anti-S2.
The relative abilities to enhance HIV infection correlated directly
with levels of SEM1 and SEM2 (Figure 6A). Consistent with
published results (Kim et al., 2010), we also observed a direct
correlation between the levels of PAP248–286/SEVI and en-
hancing activity (Figures 6B and S6C). In contrast, the levels
of the seminal proteins albumin, lactoferrin, PSA, and full-length
PAP did not correlate with viral-enhancing activity. Finally,
a statistically significant direct correlation existed between
viral-enhancing activity and reactivity to the antibodies WO1
and WO2, which recognize the general amyloid fold (O’Nuallain
and Wetzel, 2002) (Figures 6B and S5C). Taken together, these
results support roles for both SEM and SEVI amyloids in
semen-mediated enhancement of viral infection.
Semen Samples Naturally Deficient in Semenogelin
Do Not Enhance HIV Infection
Semen samples from patients with ejaculatory duct obstruction
(EDO) have low levels of SEMs because secretions from the
seminal vesicles do not effectively reach the ejaculate (Edstro¨m
et al., 2008; Pryor and Hendry, 1991). If SEMs are importantevier Inc.
Figure 4. SEM Fibrils Enhance Fusion of
Both CCR5- and CXCR4-Tropic HIV-1 to
Primary CD4+ T Cells
CD14-CD4+ T cells were infected with BlaM-Vpr-
containing 81A (A) or NL4-3 (B) virions pretreated
with 31.25 mg/ml of the indicated agitated
peptides. Peptides that formed fibrils (Figure 2) are
indicated. Shown are the averages of triplicate
samples with a representative FACS plot pre-
sented directly below. Similar results were ob-
tained using cells from three other donors. See
also Figure S3.
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from EDO patients should be deficient in this activity. Five
semen samples from EDO patients were tested for the ability
to enhance HIV-1 81A infection of TZM-bl cells. All five samples
from EDO patients completely lacked HIV enhancement
activity, in contrast to semen pooled from 20 normal donors
(Figure 7A).
We used western blots to confirm the lack of SEM in the
EDO samples. Commercially available antibodies against
SEM1/2, as well as our anti-S1 and anti-S2 antibodies, detected
SEM fragments in semen from healthy donors (Figure 7B). The
predominance of multiple SEM fragments in semen is consistent
with prior reports that PSA cleaves SEMs at multiple sites
immediately post-ejaculation (Koistinen et al., 2002; Robert
et al., 1997). In contrast to semen from healthy donors, samples
from EDO patients had very little reactivity to the SEM antibodies
(Figure 7B). Albumin levels were uniform across the samples,
suggesting the EDO samples were not simply deficient in all
proteins. Interestingly, the levels of PSA and PAP were higher
in EDO samples, possibly from over-representation of pros-Cell Host & Microbe 10, 541–550, Dtate-derived proteins in semen from
these patients (Figure 7B). These western
blot results were confirmed by ELISA
(data not shown). When we assessed
the levels of the SEVI precursor peptide
PAP248–286, we found that, whereas
the levels of full-length PAP were
increased in EDO samples (Figure 7B),
the levels of PAP248–286 were de-
creased (Figure S6). These data suggest
that the proteolytic activity necessary to
generate SEVI from PAP may be
decreased in semen from EDO patients.
In conclusion, semen samples naturally
deficient in secretions from the seminal
vesicles lack the ability to enhance HIV
infection.
DISCUSSION
Here, we identify a set of amyloidogenic
peptides derived from SEMs, the major
components of the semen coagulum.
These SEM-derived amyloid fibrils join
SEVI as semen factors that enhance
virion attachment and entry into targetcells. We further demonstrate that endogenous SEMs contribute
greatly toward the viral-enhancing activity of semen by showing
that (1) the relative enhancing activity of semen samples from
different donors correlates with SEM levels, and (2) SEM-defi-
cient semen from EDO patients lack viral-enhancing activity.
EDO patients, whose semen lacks secretions from the seminal
vesicles, represent a small subset of infertility cases. We found
that semen from these patients is deficient not only in SEMs
but also in SEVI. Because semen from EDO patients harbor
higher levels of full-length PAP (the precursor for SEVI), we
suspect that the protease responsible for cleaving full-length
PAP into the SEVI peptide may reside in the seminal vesicles.
The identity of this protease remains undetermined. Because
EDO semen samples are deficient in both SEM and SEVI
amyloids, it is unclear which species represents the dominant
enhancing activity of semen. Although it is unknown whether
SEVI or SEM amyloids contribute more toward the viral-
enhancing activity of semen, it is noteworthy that SEMs are
more abundant than PAP. While the concentration of full-length
SEM proteins is estimated at 10–20 mg/ml in semen (Yoshidaecember 15, 2011 ª2011 Elsevier Inc. 545
Figure 5. SEM Fibrils Enhance Productive
Infection of Target Cells by HIV-1
Virionswere pretreated for 5min with the indicated
concentrations of SEM fibrils and used to infect
TZM-bl cells. Cells were assayed for Tat-inducible
b-galactosidase activity 2 days later. The numbers
above the bars indicate the n-fold infectivity
enhancement relative to infection measured in the
absence of peptide. RLU/s: relative light units/
second. Shown are average values (± standard
deviations) of triplicate measurements from one of
three independent experiments that yielded
similar results. See also Figure S4.
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berg et al., 1981). Failure of the amyloid-specific WO1 antibody
to pull out SEVI from seminal fluid may be due to a higher abun-
dance of the SEM proteins. We have confirmed that WO1 recog-
nizes synthetic SEVI amyloid fibrils but not the monomeric
PAP(248–286) peptide (data not shown). However, it is also
possible that WO1 may not detect endogenous SEVI in semen,
particularly if natural SEVI exists mainly as small protofibrils
because amyloid-specific antibodies often recognize epitopes
found in mature fibrils but not prefibrillar oligomers (Kayed
et al., 2007). Furthermore, because amyloids can adopt a wide
diversity of structures (reviewed by Toyama and Weissman
[2011]), WO1 may not recognize all the different forms of SEVI
that may exist in semen. To directly assess the relative contribu-
tion of SEVI and SEM fibrils for the enhancing activity of semen,
we are developing conformation-specific monoclonal antibodies
that can selectively immunodeplete these fibrils from semen.
Regardless of which factor contributes more, a key prediction
is that HIV-infected patients with EDO will be less likely to sexu-
ally transmit HIV because semen from EDO patients completely
lacks the ability to enhance HIV infection. Testing this hypothesis
would be interesting, albeit technically challenging, because
EDO patients are estimated to represent only 1–5% of all male
infertility cases (Pryor and Hendry, 1991).
We and others observed that semen enhances HIV infection
in vitro (Bouhlal et al., 2002; Hauber et al., 2009; Kim et al.,
2010; Mu¨nch et al., 2007; Olsen et al., 2010; Roan et al., 2009,
2010), supporting a potential role for SEM fibrils and SEVI
in enhancing HIV infection during sexual transmission. In
contrast, others have reported that semen inhibits HIV infection
(Balandya et al., 2010; Martellini et al., 2009; Sabatte´ et al.,
2007). These contrasting results may reflect multiple factors,
including the presence of both enhancing and inhibitory factors
for HIV infection, inhibitory effects due to semen-mediated
toxicity on target cells, and different experimental conditions
among laboratories. Notably, the inhibitory activity reported by546 Cell Host & Microbe 10, 541–550, December 15, 2011 ª2011 Elsevier Inc.Sabatte´ et al. was specific for DC-SIGN-
dependent enhancement of trans-infec-
tion to T cells (Sabatte´ et al., 2007);
indeed, we previously confirmed the pre-
sence of this inhibitory activity (Kim et al.,
2010). Conversely, our observation that
semen enhances direct HIV infection
of multiple cell types stands in sharpcontrast with reports that semen inhibits HIV infection in vitro
(Balandya et al., 2010; Martellini et al., 2009). We have carefully
reproduced the conditions used by Martellini and coworkers,
who suggested that semen may inhibit HIV infection. Our
analysis reveals a direct correlation between semen-induced
cytotoxicity and the observed viral inhibitory activity of semen,
suggesting that the observed inhibition was likely due to low
viability of target cells (Kim et al., 2010). More recently, Balandya
et al. reported that seminal fluid inhibits HIV infection by down-
modulating a whole panel of cell-surface receptors (Balandya
et al., 2010). Because they were working with a concentration
of seminal fluid that is just at the threshold of killing target cells,
we believe that cytopathic effects of the seminal fluid likely
accounted for the observed inhibition of HIV infection. Indeed,
their observation of a general decrease in all cell-surface recep-
tors except CCR5, whose expression is increased on late
apoptotic cells (Ariel et al., 2006), suggests that the target cells
they used may have been undergoing apoptosis at the time of
infection. Furthermore, we have found that inhibitory semen
concentrations utilized by Balandya et al. are markedly cyto-
toxic for PBMCs (unpublished data). Recognizing that the
in vitro cytotoxic effects of semen can complicate its evaluation,
we have worked out and described methods for examining
the effect of semen on HIV infection under conditions that
preserve the viability of target cells (Kim et al., 2010; Mu¨nch
et al., 2007). We believe it is paramount to carry out semen
analysis under such nontoxic conditions because viral gene
expression is dependent on the fitness of cells and cytotoxic
effects may result in misleading conclusions.
Ultimately, the inhibitory or enhancing effect of semen on HIV
infection requires careful assessment in in vivo models of
mucosal HIV infection. Two studies have examined the effect
of semen on vaginal infection of rhesus macaques with SIV.
Miller et al. observed that human seminal plasma increased
the rate of transmission at low but not high levels of SIV innocula
(Miller et al., 1994). A second study reported increased vaginal
Figure 6. The Magnitude of Enhancement of HIV-1 Infection by
Individual Semen Samples Correlates Directly with the Relative
Levels of SEM Peptides and PAP248–286
(A) Direct correlation between viral enhancement activity and the quantity of
SEM1 (left) and SEM2 (right) fragments measured using the anti-S1 and anti-
S2 sera, respectively. The n-fold enhancement on the y-axis was determined
using a TZM-bl infectivity assay. Error bars reflect standard deviations of
triplicate well measurements. The relative SEM levels on the x-axis were
determined by ELISA. See also Figure S5B.
(B) Summary of all correlation analysis of viral-enhancing activity versus
reactivity to the indicated antibodies. Semen samples from 20 donors were
tested for relative viral-enhancing activity and for reactivity to the indicated
antibodies. The left column displays cases where there was a direct corre-
lation (p-values, all < 0.05, as shown) between viral-enhancing activity and
reactivity to the indicated antibody. The right column displays cases where
there was no direct correlation. See also Figure S5C.
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(Neildez et al., 1998), again only under conditions of low viral in-
nocula. Interestingly, the enhancing effects of SEVI and semen
on HIV infection in vitro are also most prominent at low viral in-
nocula (Mu¨nch et al., 2007). Unfortunately, in both of the in vivo
studies mentioned, the small number of animals examined
precluded meaningful statistical analysis. As such, the effect
of semen in a low-dose vaginal challenge study powered with
a sufficiently large number of animals to yield statistically signif-
icant results is urgently needed.Cell Host &Previous studies support the notion that SEM peptides may
form amyloids in vivo. Amyloid deposits reactive to SEM-specific
antibodies have been observed in the seminal vesicles of
patients with localized amyloidosis (Linke et al., 2005). Further-
more, localized amyloidosis of the seminal vesicles has been
detected at a frequency of 17% in men over age 50 at autopsy
(Bursell, 1942) and is thought to be a common condition
(Pitka¨nen et al., 1983). The pathogenesis of such amyloids, if
any, is unknown but our identification of SEM peptides that
spontaneously form fibrils in vitro may provide insights into this
condition.
Although the natural function of amyloid fibrils in semen, if
any, is unknown, SEMs and their fragments have numerous
roles in fertilization (de Lamirande, 2007; Robert and Gagnon,
1999). SEMs block sperm motility (Robert and Gagnon, 1996;
Iwamoto and Gagnon, 1988) and prevent sperm capacitation
(de Lamirande et al., 2001), thereby inhibiting premature
release of active sperm. SEMs also activate sperm hyaluroni-
dase, which helps degrade the egg envelope during fertilization
(Mandal and Bhattacharyya, 1995). Cleavage of the SEMs by
PSA during liquefaction is important for fertilization because
men with semen with a slow liquefaction rate are infertile (Rob-
ert and Gagnon, 1995). In addition, several lines of evidence
suggest that SEM fragments are associated with spermatozoa.
SEM fragments have been reported to bind to the posterior
head, midpiece, and tail of spermatozoa (Bjartell et al., 1996;
de Lamirande, 2007), and antibodies raised against whole sper-
matozoa were found to recognize SEM1 (Herr et al., 1986).
Interestingly, a SEM1 fragment was found within sperm nuclei,
suggesting that SEM fragments may gain entry into these cells
(Zalensky et al., 1993). Whether any of these reported activities
of SEM or SEM fragments involve SEM-derived amyloid fibrils
remains to be explored. Notably, spermatozoa are stainable
with the amyloid-binding dye Congo red (Liu and Foote,
1998), suggesting the presence of one or more bound amyloid
fibrils. It is certainly possible that SEM amyloids coat the
surface of spermatozoa. This may, in turn, promote HIV binding
to the spermatozoa and facilitate the transfer of virions to
susceptible target cells in both the lower and upper reproduc-
tive tracts (Ceballos et al., 2009).
Notably, semen is thus far the only biological fluid that has
been reported to contain multiple amyloidogenic peptides
derived from abundant proteins. PAP and SEMs, the precursors
for these amyloidogenic peptides, are proteins, whose expres-
sion is mostly limited tomale reproductive organs. The existence
of naturally occurring amyloidogenic peptides in semen may
have an evolutionary role in promoting fertilization. Since SEM
fibrils can increase HIV fusion, might they also have a role in
fertilization by enhancing sperm-egg fusion? Many parallels
exist between the fusion of HIV to cells and the fusion of sperm
to egg (reviewed in Doncel [2006]). Both processes require lipid
rafts and glycoproteins, and the molecular basis of the fusion
processes share signaling pathways and involve integrins and
tetraspanins. Furthermore, spermicidal compounds inhibit HIV
infection, whereas virucidal compounds, such as polyanions
and antimicrobial peptides, block sperm-egg fusion (Doncel,
2006). As we obtain a broader understanding of natural factors
in semen that enhance HIV infection, we may gain additional
insights into the molecular events that promote fertilization andMicrobe 10, 541–550, December 15, 2011 ª2011 Elsevier Inc. 547
Figure 7. Semen Samples from EDO Patients Lack Viral-
Enhancing Activity and Are Deficient in SEMs
(A) Pooled semen from normal donors or individual semen
samples from patients with EDO were pretreated at the indicated
concentrations with 81A virions for 5 min. Samples were then
diluted 15-fold and added to TZM-bl cells. Medium was replaced
after 2 hr, and cells were assayed for Tat-inducible b-galactosi-
dase activity 3 days later. RLU/s: relative light units/second.
Shown are average values (± standard deviations) of triplicate
measurements. The decrease in infectivity enhancement with a
semen pretreatment concentration of 50% is due to semen-
mediated toxicity to the cells (Kim et al., 2010).
(B) Semen samples from normal donors or EDO patients were
analyzed by western blot using commercial antibodies recog-
nizing both SEM1 and SEM2 (a-SEM1/2), or the anti-S1 and
anti-S2 antibodies generated for this study. Samples were also
blotted for albumin, PSA, and PAP as indicated. Note that EDO1
was not analyzed by western blot analysis due to limited material.
See also Figure S6.
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that block HIV infection by targeting viral-enhancing factors,
such as semen-derived amyloid fibrils, might also serve as
contraceptives.
EXPERIMENTAL PROCEDURES
Reagents
Custom peptides (synthesized by Celtek Peptides, Nashville, TN, and CPC
Scientific, Sunnyvale, CA) were dissolved in PBS at concentrations of 2.5–
10 mg/ml, and amyloid fibril formation was promoted by overnight agitation
at 37C at 1,400 rpm with an Eppendorf Thermomixer. Deidentified semen
samples from healthy donors (obtained from the UCSF Fertility Clinic, San
Francisco, CA) were allowed to liquefy for 2 hr at room temperature and
thenwere frozen at20C. Seminal fluid was generated by centrifuging semen
pooled from 20 donors for 30 min at 4C and collecting the supernatant.
Deidentified semen samples from patients with EDO (diagnosed by low
seminal levels of fructose because fructose in semen originates from the
seminal vesicles) were kindly provided by Ole¨ Sorensen (Lund University,
Sweden). Most infectivity experiments used seminal fluid rather than semen;
the exception was the analysis of individual semen samples because there548 Cell Host & Microbe 10, 541–550, December 15, 2011 ª2011 Elsevier Inc.was not enough material to generate seminal fluid for the assays.
Notably, the viral-enhancing activities of semen and seminal fluid
are similar (Mu¨nch et al., 2007). Use of semen samples was con-
ducted under guidelines approved by the Committee on Human
Research at the University of California, San Francisco.
Depletion of Cationic and Anionic Components
from Semen
SCX and SAX Dynabeads (Invitrogen, Carlsbad, CA) were used
according to the manufacturer’s protocol. Briefly, after washing
and equilibration, Dynabeads were incubated with 20% pooled
seminal fluid (diluted in PBS) for 1 hr at 4C. A total of four rounds
of depletion were carried out for each condition. For mock-
depleted samples, 20% pooled seminal fluid samples were
carried through the four rounds of 4C incubations in the absence
of added beads. Total protein content in the samples was deter-
mined by the bicinchoninic acid assay (Thermo Scientific, Wal-
tham, MA).
ELISA
Immunolon II plates (Fisher, Waltham, MA) were coated for
12–18 hr at 4C with 1% semen or the indicated concentration
of antigen diluted in PBS. Next, wells were blocked for 2 hr at
room temperature with 1% BSA diluted in PBS. Wells were
then incubated with sera (diluted in PBS/1%/BSA) for 1 hr atroom temperature. After washing, wells were incubated with horse radish
peroxidase-conjugated secondary antibody (GE Healthcare, South San Fran-
cisco, CA) diluted in PBS/1% BSA. After a second wash, tetramethylbenzidine
(TMB) substrate (Sigma-Aldrich, St. Louis MO) was added and the reaction
was stopped with 2M H2SO4. OD at 450/650 nm was monitored using a
spectrophotometer. Commercial monoclonal antibodies recognizing PSA
(O14) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Commercial polyclonal antibodies recognizing PAP, lactoferrin, and albumin
were purchased from Sigma-Aldrich. Amyloid-specific antibodies WO1 and
WO2were kindly provided by RonWetzel (University of Pittsburgh). Antibodies
against PAP248–286, SEM1(49–107), and SEM2(49–107) were custom-
produced by Pocono Rabbit Farms (Canadensis, PA).
Thioflavin T
125 mg/ml of agitated peptides were incubated with 5 mM Thioflavin T
(Sigma-Aldrich), and the increase in fluorescence (excitation 440 nm, emission
482 nm) in triplicate wells was assayed with an Ls-5B luminescence
spectrometer (Perkin-Elmer, Waltham, MA).
Electron Microscopy
Agitated peptides were adsorbed on glow-discharged carbon-coated grids
and negatively stained with 2% uranyl acetate. For imaging of virions with
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14,000 rpm, and the pellet was resuspended in PBS and incubated at 4C
for 1 hr. Viral particles were then incubated with 500 mg/ml SEM1(49–107)
fibrils for 10 min and fibrils were pelleted at 14,000 rpm for 10 min. Pellets
were resuspended and adjusted to a peptide concentration of 5 mg/ml and
prepared for electron microscopy. Samples were adsorbed on glow-dis-
charged coated grids, fixed with 2.5% glutaraldehyde in phosphate buffer
(pH 7.3, 0.2 M), and negatively stained with 0.5% uranyl acetate. All samples
were imaged with a Zeiss EM10 transmission electron microscope (Zeiss,
Oberkochen, Germany) at an accelerating voltage of 80 kV.
Fluorescence Microscopy
SEM1(49–107) fibrils (200 mg/ml) were added to the ProteoStat Amyloid
Plaque Detection Kit (Enzo Life Sciences, Plymouth Meeting, PA). Fibrils
were then incubated 1:1 with MLV-gag-YFP viral particles and added, where
indicated, to 50,000 TZMbl cells stained with CellTrace Violet Cell Pro-
liferation Kit (Invitrogen). Samples were transferred onto m-slides VI0.4 (Ibidi,
Munich, Germany) and imaged with a Zeiss LSM confocal microscope using
LSM 710 Release version 5.5SP1 software.
Cell Culture
Primary CD4+ T cells were isolated from buffy coats by Ficoll-Hypaque
density gradients, followed by negative selection with CD14+ microbeads
and positive selection with CD4+ microbeads (Miltenyi, Bergisch Gladbach,
Germany). The purified CD14-CD4+ cells were cultured in RPMI medium
supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/ml), and
streptomycin (50 mg/ml). 293T and TZM-bl cells were cultured in DMEM
medium supplemented with 10% FBS, L-glutamine (2 mM), penicillin
(50 U/ml), and streptomycin (50 mg/ml).
Viral Production
The CCR5-tropic 81A viruses used in TZM-bl infectivity assays were produced
by Fugene-mediated transfection (Roche, Switzerland) of 293T cells with
a proviral DNA expression plasmid. The CCR5-tropic NL4-3 92th014.12
viruses (Papkalla et al., 2002) used in TZM-bl infectivity assays were produced
by transient calcium phosphate transfection of 293T cells with the proviral
pBRHIV-1NL4-3_92Th014 expression plasmid. The BlaM-Vpr chimeric
CCR5-tropic 81A and NL43 viruses used in the fusion assays were produced
by Fugene-mediated transfection of 293T cells with proviral DNA expression
plasmids as previously described (Cavrois et al., 2002). Two days after trans-
fection, supernatants were clarified by sedimentation and titered for p24
content by anti-p24Gag ELISA (Perkin-Elmer).
Virion Fusion Assay
Virion fusion was performed similar to previously described methods (Cavrois
et al., 2002). HIV-1 virions (200 ng/ml) were pretreated with SEM or SEVI fibrils
(31.25 mg/ml) for 1 hr at 37C and then added to 5 3 105 CD14-CD4+ target
cells. To examine the effect of heparin on the viral-enhancing activity of the
SEM fibrils, target cells, rather than virions, were pretreated because heparin
has direct inhibitory effects on HIV (Roan et al., 2009). For target cell pre-
treatment, 5 3 105 CD14-CD4+ cells were incubated with the indicated SEM
fibrils (31.25 mg/ml) in the absence or presence of heparin (31.25 mg/ml,
Sigma-Aldrich) for 1 hr. After pretreatment, cells were washed three times
with medium and added to virions. Viral fusion was allowed to proceed for
4 hr at 37C, after which cells were loaded overnight with CCF2. Cells were
stained with surface antibodies against CD3 and CD4, fixed with 2% parafor-
maldehyde, and then analyzed on a BD LSRII. Flow cytometric data were
processed with FlowJo software (Treestar, Ashland, OR).
TZM-bl Infectivity Assays
Infectivity assays were essentially performed as described (Kim et al., 2010;
Roan et al., 2009). HIV-1 from the supernatant of transfected 293T cells was
diluted to 0.1 mg/ml p24 and pretreated for 5 min with peptide or semen/
seminal fluid at the indicated concentrations. Pretreated virions (20 ml) were
added to TZM-bl cells (104 /well in 96-well flat-bottom plates) in 180 ml medium
(for peptide treatment) or 280 ml medium (for semen/seminal fluid treatment).
To minimize toxic effects mediated by prolonged exposure of semen/ seminal
fluid to target cells, the medium was replaced after 2 hr, and infection wasCell Host &assayed 2–3 days later by monitoring b-galactosidase activity using the
Gal-Screen kit (Life Technologies, Carlsbad, CA). Background signals
obtained from uninfected cells were subtracted from values obtained with
infected cells.
Western Blotting
The equivalent of 0.2–1 ml of seminal fluid was loaded onto 12.5% Criterion
Tris-HCl polyacrylamide gels (Bio-Rad, Hercules, CA). Proteins were trans-
ferred onto nitrocellulose iBlot membranes (Invitrogen) and blocked with
PBS in the presence of 5% milk and 0.1% Tween-20. Commercial antibodies
against SEM1/2 and PSA (sc33819 and sc80304) were purchased from Santa
Cruz Biotechnology, commercial antibodies against albumin and PAP (A0433
and P5664) were purchased from Sigma, and custom antibodies against
PAP248–286, SEM1(49–107), and SEM2(49–107) were custom-produced by
Pocono Rabbit Farms. Primary antibodies were used at a dilution of
1:1,000–1:40,000, and HRP-conjugated secondary antibodies were used at
a final dilution of 1:5,000. Blots were developed using the Western Lightning
ECL kit (Perkin-Elmer).SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.chom.2011.10.010.
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